Faricimab is currently approved in more than 70 countries to treat nAMD and DME, with more than 1 million doses distributed globally, and Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists annual meeting in Seattle.
According to Tarsus Pharmaceuticals, lotilaner ophthalmic solution 0.25% (XDEMVY) is the first approved therapeutic for Demodex blepharitis, and has demonstrated efficacy across multiple clinical measures of disease.
The Biocon Biologics, Ltd product moves on to review by the European Commission, with an expected decision in late September 2023.
According to The Fred Hollows Foundation, an estimated $12 trillion could be added to global output by 2025 if the gender gap was closed in both the workforce and leadership.
The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.
The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on 31 July, 2023 in Seattle, Washington.
Investigators found that implementing immediately sequential bilateral cataract surgery reduced the number of patient visits by 50%.
A recent study demonstrates the safety and efficacy of treating eyes with cross-linking after keratoconus relapses following keratoplasty.
The authors suggested that future studies of myopia control should test stronger concentrations of atropine.
The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.
The 2023 41st annual meeting of the American Society of Retina Specialists (ASRS) will run from Thursday, July 27 to Tuesday, August 1 in Seattle, a city filled with sightseeing, museums, and great food to explore.
ASRS is an international, state-or-the-art event offering something for everyone: scientific papers, posters, panel discussions on controversial issues and techniques, award lectures, a Retina Case Conference, the 25th Annual Film Festival, international symposia, and subspecialty review courses.
The London-based company will use regenerative medicine to fight ocular disease.
Investigators set out to evaluate how well an AI system works when integrated into a handheld smartphone-based retinal camera to screen patients for DR using 1 retinal image in each eye.
Hundreds of previously-unknown genes could be vital for early detection and treatment.
The use of topical insulin eye drops led to a successful resolution of PEDs in 9 of 11 cases in the study.
While these injections are the standard treatment for this patient population, the investigators found a subgroup of patients who had severe visual loss between 2 consecutive intravitreal injections.
This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).
Orbis International physician spotlights the latest trends for cataract surgery training.
The open-access tool is the official registry partner of the European Glaucoma Society.
The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures and clinical research.
The company has entered a definitive agreement with Novartis to acquire Xiidra (liftegrast ophthalmic solution 5%), representing a significant opportunity for growth in prescription dry eye.
Preliminary results indicate significant improvement for patients and ‘very good safety profile’
The investigators evaluated corrective surgery procedures to determine their effect on ocular outcomes.
The company seeks to replicate European success of the ELIOS procedure in the US market.
The pharmaceutical company will present study results at the World Glaucoma Congress.
Horizon Therapeutics announced the Brazilian Health Regulatory Agency (ANVISA) has approved TEPEZZA as the first and only medicine approved in Brazil for treatment of thyroid eye disease.
The company announced the Complete Response Letter from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”
The live streamed event will cover topics including DME, CME, AON and more.
According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.
